Summary
We investigated the effect of human recombinant DNA-derived IFN-alpha-2 given in a dose of 1–2×106 units daily by subcutaneous injection to five patients with advanced idiopathic myelofibrosis (IM). Transfusion dependent anemia and symptomatic splenomegaly were taken as inclusion criteria for this pilot study. Two patients succumbed, one and three months after starting interferon-treatment because of pneumonia and traumatic cranial injury, respectively. While on IFN-treatment no improvement of cytopenia or reduction of splenomegaly was seen in four of the patients. In one patient, however, the requirement for erythrocyte transfusions decreased from 5 to 1.7 monthly upon IFN-treatment. After two, four and six months respectively IFN-treatment had to be stopped in these cases because of progressive thrombocytopenia and/or neutropenia. These observations suggest, that IFN-alpha might be of only marginal value in the treatment of advanced idiopathic myelofibrosis.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
Abbreviations
- IM:
-
idiopathic myelofibrosis
- IFN:
-
interferon
- rIFN:
-
recombinant interferon-alpha-2
- PDGF:
-
platelet derived growth factor
References
Assoian RK, Grotendorst GR, Ailar DM, Sporm MB (1984) Cellular transformation by coordinated action of three peptide growth factors from human platelets. Nature 309: 806–806
Boxer M, Ellman L, Geller R, Wang C-A (1977) Anemia in primary hyperparathyroidism. Arch Intern Med 137: 588–590
Castro-Malaspina H, Rabellino EM, Yen A, Nachmann RL, Moore MAS (1981) Human megakaryocytic stimulation of proliferation of bone marrow fibroblasts. Blood 57: 781–787
Duncan MR, Berman B (1985) Gamma-interferon is the lymphokine and beta-interferon the monokine responsible for inhibition of fibroblast collagen production and late but not early fibroblast proliferation. J Exp Med 162: 516–527
Georgii A (1983) Histopathologie und Klinik der chronischen myeloproliferativen Erkrankungen. Verh Dtsch Ges Pathol 67: 214–234
Georgii A, Thiele J, Vykoupil KF (1980) Osteomyelofibrosis/-sclerosis. A histological and cytogenetic study on core biopsy of the bone marrow. Virchows Arch A Pathol Anat Histol 389: 269–286
Groopman JF (1980) The pathogenesis of myelofibrosis in myeloproliferative disorder. Ann Intern Med 92: 857–858
Gruchy GC de (1978) In: Penington D, Rush B, Castaldi P (eds) Clinical Haematology in Medical Practice, 4th Edn. Blackwell Scientific Publications, Oxford London Edinburgh Melbourne, pp 583–600
Jiminez SA, Freundlich B, Rosenbloom J (1984) Selective inhibition of human diploid fibroblast collagen synthesis by interferons. J Clin Invest 74: 1112–1116
Linkesch W, Gisslinger H, Ludwig H, Sinzinger H (1985) Therapie exzessiver Thrombozytosen bei myeloproliferativen Erkrankungen mit rekombinanten Interferon alpha 2-C. Acta Med Austriaca (Suppl) 12: 48 (abstract)
Mc Carthy DM (1985) Annotation. Fibrosis of the bone marrow: Content and causes. Brit J Haematol 59: 1–7
McCarthy DM, Hibbin JA, Holmand JM (1984) A role for 1.25-hydroxyvitamin D3 in control of bone marrow collagen desposition? Lancet I: 78–80
Niederle N, Kloke O, Doberauer C, Becher R, Beelen DW, Schmidt CG (1986) Alpha-2 Interferon: erste Behandlungsergebnisse bei der chronisch myeloischen Leukämie. Dtsch Med Wochenschr 111: 767–772
Rigby WFC, Ball ED, Guyre PM, Fanger MW (1985) The effects of recombinant-DNA-derived interferons on the growth of myeloid progenitor cells. Blood 65: 858–861
Talpaz M, McCredie KB, Mavligit GM, Guttermann JU (1983) Leukocyte interferon-induced myeloid cytoreduction in chronic myelogenous leukemia. Blood 62: 689–692
Talpaz M, Kantarjian HM, McCredie KB, Trujillo JM, Keating MJ, Guttermann JU (1986) Hematologic remission and cytogenetic improvement induced by recombinant human interferon alphaA in chronic myelogenous leukemia. N Engl J Med 314: 1066–1069
Ward HP, Block MH (1971) The natural history of agnogenic myeloid metaplasia (AMM) and a critical evaluation of its relationship with the myeloproliferative syndrome. Medicine 50: 357–420
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Seewann, H.L., Gastl, G., Lang, A. et al. Interferon-alpha-2 in the treatment of idiopathic myelofibrosis. Blut 56, 161–163 (1988). https://doi.org/10.1007/BF00320746
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00320746